Goldman Sachs Group Inc. Acquires 119,145 Shares of Replimune Group, Inc. $REPL

Key Points

• Goldman Sachs Group Inc. increased its stake in Replimune Group, Inc. by 20.9%, acquiring 119,145 shares, giving it ownership of approximately 0.90% of the company valued at $6.7 million.
• Analysts have recently downgraded the stock with BMO Capital Markets slashing its price target from $27 to $2, while others like JPMorgan and Wedbush have also reduced their ratings.
• Replimune Group reported a loss of ($0.95) EPS for the last quarter, missing estimates by $0.12, contributing to bearish sentiment among analysts.

Goldman Sachs Group Inc. lifted its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 20.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 690,167 shares of the company's stock after buying an additional 119,145 shares during the period. Goldman Sachs Group Inc. owned about 0.90% of Replimune Group worth $6,729,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Nuveen Asset Management LLC increased its stake in shares of Replimune Group by 108.9% in the 4th quarter. Nuveen Asset Management LLC now owns 667,634 shares of the company's stock valued at $8,085,000 after buying an additional 347,993 shares during the period. GAMMA Investing LLC raised its holdings in Replimune Group by 897.2% in the first quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock worth $902,000 after purchasing an additional 7,913 shares during the period. ProShare Advisors LLC boosted its position in shares of Replimune Group by 33.8% during the fourth quarter. ProShare Advisors LLC now owns 20,788 shares of the company's stock worth $252,000 after purchasing an additional 5,247 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Replimune Group by 352.5% in the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock valued at $13,282,000 after buying an additional 854,346 shares during the period. Finally, California State Teachers Retirement System increased its stake in Replimune Group by 25.9% during the 4th quarter. California State Teachers Retirement System now owns 42,725 shares of the company's stock worth $517,000 after purchasing an additional 8,793 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. restated a "neutral" rating and set a $9.00 target price (down from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. HC Wainwright restated a "neutral" rating on shares of Replimune Group in a research report on Monday, September 8th. BMO Capital Markets lowered Replimune Group from an "outperform" rating to an "underperform" rating and reduced their price objective for the company from $27.00 to $2.00 in a research note on Wednesday, July 23rd. Barclays cut shares of Replimune Group from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $17.00 to $3.00 in a research note on Wednesday, July 23rd. Finally, Wedbush reiterated a "neutral" rating and issued a $4.00 price objective (down previously from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Two investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $6.50.

Replimune Group Price Performance

Replimune Group stock opened at $5.73 on Monday. The business's 50 day simple moving average is $6.68 and its 200 day simple moving average is $8.41. Replimune Group, Inc. has a 12 month low of $2.68 and a 12 month high of $17.00. The company has a market cap of $447.28 million, a price-to-earnings ratio of -1.77 and a beta of 0.51. The company has a current ratio of 6.94, a quick ratio of 6.94 and a debt-to-equity ratio of 0.21.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Sell-side analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the transaction, the chief financial officer directly owned 134,368 shares in the company, valued at approximately $721,556.16. This represents a 6.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.20% of the stock is owned by insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.